Nexentis Technologies Inc. (NASDAQ:NXTS) experienced sharp trading volatility on Wednesday after announcing a research breakthrough at its biotechnology subsidiary, MitoCareX Bio.
The stock initially surged as much as 30% following the news before reversing course and trading about 2% lower later in the session.
MitoCareX Expands Analysis of SLC Transport Proteins
The company said MitoCareX has completed a broad structural assessment of human Solute Carrier (SLC) transport proteins, a project designed to strengthen its small-molecule drug discovery platform.
The research builds on MITOLINE, the subsidiary’s proprietary sequence analysis and alignment technology, which has previously been used to prepare mitochondrial SLC25 carrier proteins for three-dimensional modeling applications targeting difficult-to-treat cancers and inflammatory metabolic disorders.
Findings Could Broaden Drug Discovery Opportunities
According to the company, the analysis identified additional SLC proteins outside the SLC25 family whose amino acid structures appear compatible with the MITOLINE framework.
As a result, MitoCareX plans to investigate whether MITOLINE-generated 3D models can be incorporated into virtual screening programmes focused on selected non-mitochondrial SLC targets.
Management believes this approach could extend the platform’s applicability to a wider range of disease-relevant transport proteins and potentially unlock new therapeutic opportunities.
Computational Platform Remains Central to Strategy
The subsidiary aims to expand the number of clinically significant transporters it can address while maintaining a computationally driven discovery process.
By leveraging advanced modeling and screening techniques, MitoCareX is seeking to accelerate the identification of promising small-molecule candidates without relying solely on traditional laboratory-intensive methods.
The company views this strategy as an efficient way to broaden its drug development pipeline.
Management Highlights Recent Progress
David Palach, Chief Executive Officer of Nexentis, said the latest achievement follows recent advances made by MitoCareX, including the announcement of an optimized hit molecule.
He noted that the new findings demonstrate both the flexibility and potential of the MITOLINE platform, as well as the company’s ability to identify additional transporter targets that may benefit from MITOLINE-enabled 3D modeling.
Diversified Business Model
Nexentis operates as a drug discovery company focused on developing novel therapeutic candidates through its biotechnology activities.
In addition to its life sciences operations, the company also invests in solar energy projects using a Ready-to-Build (RTB) development model, providing exposure to both healthcare innovation and renewable energy infrastructure.
The latest update highlights continued efforts to expand the scientific reach of its drug discovery platform while advancing new opportunities for future research and development.